The European Medicines Agency argued that regulators should prioritize generating strong, decision-relevant evidence rather than adhering to a fixed “one pivotal study” or “two trial dogma” standard for approval. EMA leaders referenced the FDA’s evolving posture while emphasizing that replication is not the only purpose of multiple trials. The EMA editorial stressed that second trials can explore effects in different populations, settings, or study conditions, and that rigid default trial-count requirements would undermine core goals of clinical development programs. The message reinforces how both regulators are recalibrating expectations for evidence packages as methods and analytics evolve. For biotech developers, the guidance affects trial design strategy—particularly when sponsors seek label expansion, faster timelines, or rely on biomarker-enriched designs.